Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Related Articles

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?

Oncotarget. 2017 Mar 23;:

Authors: Tian Z, Jing W, Yanjun S, Xi C, Qingna Y, Qi L, Leina S, Yuwen W, Puchun E, Qingsong P, Ping W

Abstract
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome 7. This study aimed to investigate the clinicopathologic characteristics of classic EGFR exon mutation in Chinese patients with TMN stage III lung adenocarcinoma who received radical surgery. A total of 1,801 lung adenocarcinomas were analyzed for mutations in EGFR; 35% exhibited mutation of classic EGFR exons. Clinical and pathologic characteristics of patients with EGFR exon 19 mutation were compared with those who harbored EGFR exon 21 mutation. Patients with EGFR exon 19 mutation had a higher overall survival (OS, p=0.023) than those harboring EGFR exon 21 mutation. Our results demonstrated that patients with a micropapillary pattern (MPP) pathologic type in EGFR exon 19 mutation had a higher OS (p=0.022), and patients with exon 19 mutation were more sensitive to EGFR-tyrosine kinase inhibitors (p=0.032). The results of the current study can be used in decision-making regarding the treatment of patients with classic EGFR exon mutations.

PMID: 28380449 [PubMed - as supplied by publisher]

http://ift.tt/2oPI4d6